Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 21 - 30 of about 173   

Articles published

GSK 1,326.00 -13.00 (-0.97%)
price chart
Director Deals - GlaxoSmithKline PLC (GSK)
Director Deals - GlaxoSmithKline PLC (GSK). 20 October 2014 | 17:05pm. - Andrew Witty, Chief Executive Officer, has re-invested 1,434 shares in the company on the 3rd October 2014 at a price of 1411.09p.
Related articles »  
Turn �10k Into �18.5k With GlaxoSmithKline plc
The FTSE 100's other big pharmaceuticals company, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) hasn't been doing quite so well - for one thing, it hasn't had its shares boosted by takeover fever.
GlaxoSmithKline plc Given "Neutral" Rating at Killik (GSK)  sleekmoney
GlaxoSmithKline plc Receives Hold Rating from Deutsche Bank (GSK)  Watch List News (press release)
Related articles »  
3 Stocks To Transform Your Portfolio: HSBC Holdings plc, GlaxoSmithKline plc ...
Sometimes, it's difficult to find high-quality companies trading at attractive valuations. Indeed, during bull markets it can be especially tough, as valuations become rather excessive.
Related articles »  
Why GlaxoSmithKline plc Should Lag The FTSE 100 This Year
Announced on 19 September, the Chinese court found that Glaxo's Chinese subsidiary had illegally �offered money or property to non-government personnel in order to obtain improper commercial gains, and been found guilty of bribing non-government ...
Analysts' Recent Ratings Updates for GlaxoSmithKline plc (GSK)  WKRB News
Short Interest in GlaxoSmithKline plc Increases By 36.2% (GSK)  Ticker Report
Related articles »  
Why GSK Has Been Immune To Ebola Gains
Some companies are also working on a vaccine for Ebola, of which NewLink and GSK are at an advanced stage. GSK has already started human trials in the US and UK and is manufacturing 10,000 doses of the vaccine, whose use is contingent on the ...
Ebola Vaccine Trials May Give Placebo to Those at Risk  Businessweek
Related articles »  
GSK Expects Delayed Production Of Ebola Vaccine
GlaxoSmithKline plc (ADR) (GSK) announced today that it might not be able to develop its Ebola vaccine in time to control the epidemic.
GSK share price: Ebola vaccine to come 'too late' for current outbreak  iNVEZZ
U.K.'s Glaxo Working to Accelerate Treatment for Ebola Virus
Related articles »  
Can Dividend Stock GlaxoSmithKline plc Bounce Back?
Given the widespread nature of this problem, Western authorities have taken a keen interest in the activities of their biopharmaceutical companies both abroad and at home.
Related articles »  
Why I Bought GlaxoSmithKline plc
Investing is akin to predicting the future, but while I can't tell you exactly how the world will look in 10 years' time, I can tell you what will be the same.
Credit Suisse Reaffirms "Underperform" Rating for GlaxoSmithKline plc (GSK)
GlaxoSmithKline plc (NYSE:GSK)'s stock had its �underperform� rating reaffirmed by equities research analysts at Credit Suisse in a research note issued to investors on Wednesday.
GlaxoSmithKline Starts First Human Trials For Ebola Vaccine In Africa
The first ever human trials for an Ebola vaccine started yesterday in Mali, where healthcare workers are being administered with GlaxoSmithKline plc's (ADR) (GSK) chimpanzee-adenovirus vaccine shots. There are no Ebola cases in Mali so far. However ...
Related articles »